

Elanco™



Insight for healthier
business decisions

Elanco™


HTSi
Annual Report
2025



Elanco**HTSi****Insight for healthier
business decisions**

- 3 What is HTSi?**
- 4 Best practice**
- 5 Global reach**
 - HTSi internationally
- 6 2024 in the UK**
 - Postings by age
- 7 Intestinal Integrity (I²)**
 - Proven business benefits
 - Trends over time
 - I² across Europe
 - Key contributors
 - Gizzard health
- 10 Coccidiosis**
 - E. acervulina* trends
 - E. maxima* trends
 - E. tenella* trends
- 13 2024 coccidiosis peaks**
 - Market comparison
- 14 Coccidiosis peaks by year**
- 16 Locomotor health**
 - Leg health over time
 - Pododermatitis
- 17 Veterinary comments**
- 18 Solutions to support Intestinal Integrity**
- 22 Sustainability – a core value**

Report created from 2024 data



What is HTSi?


Developed to enable poultry businesses to make informed decisions towards future improvements, Elanco's Health Tracking System (HTSi), is an established, independently verified and data-led broiler benchmarking platform.

Globally recognised, HTSi monitors the health and performance of birds, incorporating multiple lesions to assess intestinal health, respiratory stability, locomotor function and bird welfare.¹



Best practice

HTSi enables producers to monitor the general health of their birds. Establishing trends requires consistent HTSi sessions, as well as a selection of birds that represent the company. This means birds from a wide range of ages, and from a variety of farms to ensure that data captured is representative of the whole flock health.




Global reach


Recognised globally, HTSi is trusted by **350 poultry businesses in 60 countries**. In 2024, **317 businesses** used routine HTSi sessions as a way to make informed decisions around flock health.

2024

The three countries with the highest averages this year are:



Number of Birds vs. Region in 2024



2024 in the UK

As part of Elanco’s value adding HTSi, the team continued to travel around the UK, collecting meaningful data to provide customers with trusted expertise and information to make better business decisions.

4,862 birds
necropsied

217 farms
539 houses

8 broiler
companies
covered

By a team of
8 Technical
Experts




Postings by age

HTSi sessions in 2024 included birds ranging from 10 to 39 days of age, with an average of 25.3 days. The majority of sessions were held between 18 and 32 days. Our extensive data base ensures a wide range of bird ages can be covered, allowing insights into intestinal health at most ages.


Ross - 94.8%

Hubbard - 4.8%

Cobb - 0.4%




The prevalence of both Hubbard and Cobb have slightly increased compared to 2023 data, however the impact on the prevalence of Ross 308 birds was minimal at -0.6%



Intestinal Integrity (I²)

Developed to consistently and reliably assess intestinal health, the Intestinal Integrity (I²) index has been twice independently validated.^{1,2} It assesses 23 intestinal health lesions via a unique weighted algorithm to give a score out of 100.



Proven business benefits


At current feed prices³ a poultry company producing 100 million broilers per year, partnering with Elanco to improve the I² index by 5 points could mean an annual income boost of:

£497,640⁴

By understanding the current challenges and seasonal trends, proactive intervention can reduce potential losses. Identifying the opportunities to improve ADG, FCR, EPEF and percent livability.^{1,2}


The I² index, combined with information contained in the HTSi database, could be used to identify the yield gaps in production and suggest possible interventions to close these gaps.

Alexandra L. Swirski et al., Novometrix Research Inc.



Intestinal Integrity

Trends over time



Over the course of 2024, Intestinal Integrity has improved, with a more stable average across the year, similar to that of 2023 and 2021. This was driven by high I^2 averages seen in April and August, finishing strong with December's average the highest of the past five years - with the year ending on the highest I^2 average seen across the 12 months - 96.8.

I^2 across Europe

The below diagram shows the average I^2 score in each region in 2024.



* data from May to September in both 2022 and 2024, p value = <0.0001




Intestinal Integrity

A total of 23 different lesions sit behind the Intestinal Integrity score. The data below shows the most common lesions, aside from coccidiosis, seen in HTSi sessions in 2024.


Key contributors

Excessive intestinal mucus, cellular sloughing and watery intestinal contents remained the most common I² lesions seen:



Gizzard health

After an increase in gizzard erosions was seen from 2022 to 2023, 2024 shows a slight decrease from 26% prevalence to 21.1%.




Of the ulcerations noted in 2024, 91.3% were low level (score 1), 7.4% were moderate, consistent with a score of 2. Severe (score 3) erosions made up 1.3% of the total birds affected. The most common age for birds to see mild (score 1) gizzard erosions was 24 days, where more severe erosions were most frequent at 27 days.




Coccidiosis – *E. acervulina*


A malabsorptive species of coccidiosis, *E. acervulina* is characterised by white scars on the inside of the intestine, commonly in the duodenal loop. In 2024, **32.5% of birds were affected** by this species, a reduction of 4% from 2023 levels.



E. acervulina trends




Overall, levels of *E. acervulina* in 2024 were the lowest recorded in the HTSi dataset in the past five years. The reduction seen in 2023 continued throughout the first half of 2024, with April's average the lowest since April in 2020. A stable summer period was followed by an expected seasonal increase in September, the highest average seen in the year. Since then, levels over the last quarter of the year have reduced, although December's average is marginally above what was seen the same time last year.




Coccidiosis – *E. maxima*


The most detrimental coccidia species to a farm’s performance and profits, *E. maxima* damage causes red petechiae on the outside of the intestinal tract. In 2024, **11.2% of birds** were seen to have gross lesions, confirmed by microscopy. This is an **increase from 10.6% from last year**, showing the increase of *E. maxima* incidences has not yet returned to 2021 levels.



E. maxima trends




Levels of recorded *E. maxima* in 2024 remain elevated. Whilst May and September presented birds with the most lesions, the average incidence was lower than the peak seen in 2024. The last three months of the year saw a decline in *E. maxima* lesions, levels have not yet returned to the stability seen in 2020 and 2021.




Coccidiosis – *E. tenella*


Whilst clinical cases are rarely seen on farm as part of HTSi surveillance, **5.1% birds in 2024** presented with gross *E. tenella* lesions, reduced from 10.6% in 2023. This is the only common coccidia species that will cause mortality in the birds.



E. tenella trends



Whilst incidences of *E. tenella* have been more prevalent since 2022, the overall average remains on the same scale as the previous *E. acervulina* and *E. maxima* graphs and continues to have minimal impact on UK flocks in this data set. Starting the year with a similar frequency to 2023, the average score increased in April and May, after which it has continued to decrease throughout the rest of the year.




Less moderate and severe lesions were noted this year compared to 2023.



Coccidiosis peaks

2024 coccidiosis peaks by species




The age at which birds most commonly were affected by *E. acervulina* has moved back 1.5 days from 2023 data, to 24.5 days of age.

E. maxima was noted in low levels from 20 days onwards, the most common age was 38.5 days.

Minimal *E. tenella* was recorded in 2024, with no obvious peak age.

Coccidiosis peaks by market type

There was a significant difference^ between conventionally grown birds and slower growing breeds, with conventional birds showing higher levels of *E. acervulina*, yet slower growers showing higher levels of *E. maxima* and *E. tenella*.




^p value = <0.0001




Coccidiosis peaks by year

The following graphs show how the peaks of coccidiosis have moved, if at all, year on year.

E. acervulina vs bird age




E. maxima vs bird age



Coccidiosis peaks by year

E. tenella vs bird age




Whilst still low, levels of *E. tenella* were noticed in birds over 35 days, more than any other age. Although year on year data at this stage of the bird’s life is limited, 2024 shows a higher average than other years where birds older than 37 days were necropsied. The increase in slower growing breeds could correlate with this, although more data is needed to be conclusive.




Locomotor health

Leg health over time



Pododermatitis



Veterinary comments

From Joshua Davison MRCVS –
Poultry Technical Consultant, Elanco.

The poultry industry again weathered an impressive array of intra-industry and macroeconomic challenges throughout 2024, that will likely have repercussions for 2025. These effects were further complicated by the wet and mild weather for 2024 throughout the country. Therefore, it is pleasing to see another year of HTSi data that reinforces the impressive way the UK poultry industry continues to adapt and efficiently produce affordable protein from healthy birds.

Elanco's Intestinal Integrity (I²) metric encompasses a broad range of bird health measurements that enable objective comparisons over time. **The 2024 data was robust with peak I² found in November and December, continuing the recovery from a comparatively weak 2022 (page 8). Key to this was the continued and stable coccidiosis control strategies implemented by growers.** Within the contributors to I², cellular sloughing, intestinal mucus and watery contents were the most prevalent findings, all with subtle decreases compared to 2023 (page 9).

Low coccidia lesion scores indicate coccidiosis was well managed throughout 2024; *E. acervulina* scores were at their lowest level for the previous five years, while *E. maxima* and *E. tenella* were similarly low to 2023. *E. tenella* scoring in older birds showed a small increased incidence compared to prior years that may warrant ongoing monitoring and investigation if thought to be clinically significant (page 12). **It must be remembered that these coccidia lesion score changes are subtle, when compared to the graph axes scales, in keeping with the low level of clinical coccidiosis observed. Between Eimeria species, significant differences were found between different markets; 'conventional' birds having greater *E. acervulina* scores, with less *E. maxima* and *E. tenella* scores than 'slower growing' birds (page 13).** These findings may be expected due to the differing production systems and age profiles but are worth bearing in mind with possible future retailer demands.

Looking to 2025, the vagaries of avian influenza and the continued implementation of reduced stocking densities likely present the most pressing challenges. While the stocking density changes may impact producer and retailer logistics, at the bird level the potential disease pressure within a shed is still high. During this time, minimising other on farm management changes and continuing with effective and proven disease management strategies is an imperative. Effective and consistent drying out during turn around time is the most effective control strategy for coccidia oocyst management; careful planning will be required to reduce any negative impact on turn around times during a pressured time if each bird is to achieve peak performance.


Wishing you and your businesses the best for a prosperous 2025.




Solutions to support Intestinal Integrity

Ionophores


Used since the 1970’s, ionophores are still an effective and efficient tool to improve Intestinal Integrity, and evidence of resistance to these compounds is virtually non-existent. Ionophores are classified as antimicrobials and have a wide-spectrum effect against several micro-organisms, however, they are not used in human medicine and there is currently no scientifically proven association between bacterial resistance and ionophores, the below video demonstrates the complex mode of action.



Use MAXIBAN™ in combination with MONTEBAN™ for stable coccidiosis population control. Consistently trusted by poultry producers to protect against the effects of coccidiosis for over 25 years.



Want to achieve stable & continuous coccidiosis control?



Solutions to support Intestinal Integrity

β-mannans

Beta-mannans are anti-nutritional factors (ANFs) in the diet and indigestible for monogastric animals. They are:



Found in common vegetable feed ingredients





Soluble, so easily distributed throughout the GI tract



Not affected by feed processing

As **similar mannose structures** are found in **cell surfaces of many pathogens**, animals **mistake β-mannans as a pathogen** and initiate a wasteful immune response - Feed Induced Immune Response (FIIR)

Hemicell™ breaks down β-mannans avoiding FIIR in the birds enabling them to utilise energy from the feed for body maintenance or growth.



Hemicell™ XT stops the expensive effects of β-Mannans The patented energy sparing enzyme, breaks down β-Mannans to completely prevent the Feed induced immune response (FIIR) and waste of energy that they cause.^{10,11}

Recent meta-analysis on global HTSi data has revealed the extent of the impact of FIIR on the I² index, producing a **FIIR FACTOR OUT OF 100**

Scan the QR code to watch how Hemicell™ breaks down beta mannas inside the bird



Solutions to support Intestinal Integrity

GalliPro® Fit

The easy choice.

A probiotic with a unique triple strain *Bacillus* combination, that positively influences the gut microbiome and promotes Intestinal Integrity.

Maximum benefit

GALLIPRO® FIT unlocks the nutritional potential of your feed¹²

GALLIPRO® FIT combines three naturally occurring *Bacilli* strains that were carefully selected to effectively inhibit undesirable bacteria, as well as produce beneficial enzymes.

This increases nutrient availability from the feed and can lead to improvements in feed conversion and bodyweight under commercial conditions.^{12,13}

1

B. subtilis (DSM32324):

Competes with gram negative and positive microbes;¹⁴ improves protein availability¹⁵

2


B. subtilis (DSM32325):

Competes with gram negative and positive microbes¹⁴

3

B. amyloliquefaciens (DSM25840):

Improves energy availability from non-starch polysaccharides;¹⁵
Improves protein digestibility¹⁵



GALLIPRO® FIT promotes normal gut function by outcompeting undesirable bacterial species

The three *Bacillus* strains in GALLIPRO® FIT were carefully selected to:

1. Rapidly colonise the intestine;
2. Form a beneficial biofilm in the gut which acts as a physical barrier to undesirable bacterial species;¹⁶
3. Produce lipopeptides (Surfactins and Fengycins) known to be inhibitory to some undesirable bacterial species;¹⁷
4. Have superior siderophore activity, meaning undesirable bacterial species don't have the essential iron that is needed for survival.¹⁸


Solutions to support Intestinal Integrity

Targeted to where it is needed

The *Bacillus* species in GALLIPRO® FIT are proven to colonise and protect a healthy proportion of the gut¹⁶

The *Bacillus* strains in GALLIPRO® FIT have been shown to form a beneficial biofilm in the gut. By successfully colonising and establishing a healthy proportion of the gut microbiome, these strains act precisely where they are needed.


That means they can inhibit undesirable bacteria and optimise nutrient absorption – both key factors that can contribute to improved body weight.^{13,16}



For the best outcomes

GALLIPRO® FIT can improve productivity in your broiler flock


Under commercial conditions, GALLIPRO® FIT improves several outcomes to maximise performance.




Sustainability – a core value

Elanco’s long-term commitment

This mindset is embodied by Elanco’s ‘Healthy Purpose’ sustainability approach - a framework of decade-long commitments and actions that are focused on advancing the well-being of animals, people and the planet. As part of this Elanco is leading the way to a sustainable future for poultry producers working with Blonk, a leading international expert in food system sustainability to develop lifecycle assessments (LCA) to calculate and analyse the environmental impacts of our products.



Sustainability – a core value




1 KG = ~ 3.3 KG CO2EQ

1 kg of Chicken has carbon footprint = ~3.3 kg CO2eq. Compound feed contributes ~70% of the total carbon footprint of chicken sold at the supermarket, therefore any reduction in footprint of compound feed has a significant impact on the final meat product. This will need a series of incremental improvements. Hemicell™ XT is one such improvement.²³



1 KG = 1.8 KG CO₂EQ

The carbon footprint of 1 kg Hemicell™ XT is 1.8 kg CO₂ eq.²³



2.7-3.3%

Use of Hemicell™ XT as a feed additive in broiler diets leads to a reduction in carbon footprint ranging from 2.7% to 3.3% (Depending on the growth phase scenario).²³



Net benefit due to feed efficiency:

Because the inclusion rates of feed additives are relatively low, they do not make up a significant portion of the total footprint of feed. When set against the significant improvements in feed efficiencies from using products like Maxiban™ and Monteban™ there is a very large net benefit in terms of footprint.

Minimal impact on poultry feed:

Both Maxiban™ and Monteban™ contribute less than 0.3% to the overall environmental footprint of a typical European broiler diet, despite their inclusion rates. This minimal impact is due to the relatively small amounts used in feed formulations.

<0.3%

overall environmental footprint



Elanco



**Insight for healthier
business decisions**

For further information or queries on anything in the Elanco Annual Report, please contact the Elanco team on the following email address:

poultry@elancoah.com

References:

1. Kasab-Bachi H, Arruda A, Roberts T, Wilson J. (2017). The use of large databases to inform the development of an intestinal scoring system for the poultry industry. Preventive Veterinary Medicine, 146, pp. 130–135.
2. Swirski AL, Kasab-Bachi H, Rivers J, Wilson JB. (2020). Data Driven Enhancements to the Intestinal Integrity (I2) Index: A Novel Approach to Support Poultry Sustainability. Agriculture; 10(8):320.
3. DEFRA (2025) *Average Compound Feed Prices by Main Livestock Categories – GB*. Available at: commodityprices-compounds-14nov24.ods (Accessed 6 January 2025).
4. Elanco DOF Annual Report FCR Calculation 2024
5. For a company producing 100 million birds per year on a full Maxiban™ and Monteban™ programme compared to a Monensin/Nicarbazin and Salinomycin programme for 3 crops of the year. Elanco data on file REF-22071
6. Elanco, 2018: HTSi UK Data 2015-2018 / Performance data 2014-2018 – Tom Hepburn – EKS Specialist
7. Watkins KL, Baker KT, Salois MJ. (2017). Observational analysis of broiler production and health data collected during the transition to a raised without antibiotic program. Poult. Sci. 96 (Suppl. 1).
8. Lanckriet A, Timbermont L, De Gussem M, Marien M, Vancraeynest D, Haesebrouck F, Ducatelle R, Van Immerseel F. The effect of commonly used anticoccidials and antibiotics in a subclinical necrotic enteritis model. Avian Pathol. 2010 Feb;39(1):63-8. doi: 10.1080/03079450903505771. PMID: 20390538.
9. Blake DP *et al.* (2020). Re-calculating the cost of coccidiosis in chickens
10. Daskiran, M., Teeter, R., Fodge, D. and Hsiao, H. 2004. "An Evaluation of Endo-β-D-mannanase Hemicell™) Effects on Broiler Performance and Energy Use in Diets Varying in β-mannan Content." Poultry Sci. 83: 662-668.
11. Lee, J., Bailey, C. and Cartwright, A. 2003. "β-Mannanase Ameliorates Viscosity-Associated Depression of Growth in Broiler Chickens Fed Guar Germ and Hull Fractions." Poultry Sci. 82: 1925-1931. 17. Hemicell EMEA field experience
12. Bostvironnois, *et al.* (2023) Supporting normal function of the gastro-intestinal tract with effective probiotics. Poster - International Poultry Scientific Forum, Atlanta I 23-24 January, 2023
13. Chr. Hansen Laboratories, '28 trials data'
14. Chr. Hansen Laboratories - multiple trials; 'Individual strain undesirable bacteria inhibition'
15. Chr. Hansen Laboratories - Trial no. 80375
16. Konieczka, *et al.* (2018) Effects of pea extrusion and enzyme and probiotic supplementation on performance, microbiota activity and biofilm formation in the broiler gastrointestinal tract. British Poultry Science, 59:6
17. Chr. Hansen Laboratories - Peacock Project, 2020
18. Meuter, *et al.* (2023) A triple strain probiotic demonstrates high siderophore activity: a new step towards the understanding of pathogen inhibition in poultry. Poster - International Poultry Scientific Forum, Atlanta I 23-24 January
19. Chr. Hansen Laboratories, Trial No. 80559
20. Clavé H.& Van der Horst F., 2004. Essai de comparaison de différentes préventions anticoccidiennes chez le poulet label à chair jaune. Sciences et Techniques Avicoles. April 2004, N°47
21. Williams, R. 1999. "A compartmentalized model for the estimation of the cost of coccidiosis to the World's chicken production industry". Int Journ.for Parasitology. 29(8):1209-1229
22. Salois M, Heskett E. (2017). Raised without antibiotics can lead to more use of medically important antibiotics, unpublished.
23. Blonk consultants. (2023) A lifecycle assessment (LCA) of both Hemicell production and the comparative performance of feeds containing it. Data available upon request. Int ref no. 23491

Elanco UK AH Limited, First Floor, Form 2, Bartley Way, Bartley Wood Business Park, Hook RG27 9XA. Telephone: 01256 353131 Email: elancouk@elanco.com

Elanco Health Tracking System (HTSi), Elanco, Hemicell XT, Monteban, Maxiban and the diagonal bar logo are trademarks of Elanco or its affiliates. GalliPro® Fit, a product of Chr. Hansen, distributed by ELANCO. ©2025 Elanco or its affiliates. Date of preparation: 01/2025 PM-UK-25-0030. 6854.001

Use medicines responsibly. www.noah.co.uk/responsible. Prescription decisions are for the person issuing the prescription alone.

